Skip to main content
2023 Guide to Patient Support Services

Daiichi-Sankyo & AstraZeneca

2023 PSS Guide

Daiichi-Sankyo and AstraZeneca Enhertu4U Support Program


Daiichi-Sankyo and AstraZeneca offer the Enhertu4U support program to provide information and assistance to patients who have been prescribed Enhertu (Table).

Enhertu4U Support Program

Patient Savings Program

Eligible patients may pay as little as $0 per Enhertu prescription, up to $26,000 per calendar year. To qualify, patients must:

  • Have a valid prescription for Enhertu
  • Be a resident of the United States or Puerto Rico
  • Have commercial insurance that does not cover the full cost of Enhertu
  • Not be covered by state or federal insurance, including Medicare Part B or Part D, Medicaid, Medigap, Veterans Affairs, or TRICARE.
    Other restrictions may apply.

To enroll your patient, visit or call 833-364-3788.

Patient Assistance Programs

The Patient Assistance Programs provide Enhertu at no cost to qualifying uninsured, underinsured, or Medicare patients who are having financial difficulty affording their medication. To be eligible, patients must:

  • Be residents of the United States
  • Have an annual income at or below a certain level
  • Not have insurance, private or government (excluding Medicare), that covers Enhertu
  • Not be receiving any other assistance to help pay for Enhertu.

If the patient is a Medicare beneficiary, the patient:

  • Must not be eligible for or enrolled in Low Income Subsidy for Medicare Part D
  • Must have spent at least 3% of their annual household income on prescription medicines in the current year.

If the patient has experienced a life-changing event in the past year, and financial documentation does not accurately reflect the current situation, the patient may still meet the criteria to enroll and is encouraged to apply.

Click here to enroll your patient online.

Product Request Form

For patients already enrolled in the Patient Assistance Program, the product request form may be used to request the patient’s next dose of Enhertu. The form can be accessed here.

Independent Foundations

Assistance may also be available through independent foundations. Although not associated with Daiichi-Sankyo or AstraZeneca, names and links to several foundations are available online.

TABLE Daiichi-Sankyo and AstraZeneca’s Oncology Drug

Patient support programs

Enhertu (fam-trastuzumab deruxtecan-nxki) for injection
Treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti–HER2-based regimen in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy; treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy; treatment of adult patients with unresectable or metastatic non–small-cell lung cancer whose tumors have activating HER2 mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy; treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen
Patient support programs

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"